S2Medical AB (publ)
STO:S2M
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
S2Medical AB (publ)
Operating Income
S2Medical AB (publ)
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Operating Income
-kr2.7m
|
CAGR 3-Years
54%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Operating Income
-kr46.8m
|
CAGR 3-Years
22%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Operating Income
kr94.4m
|
CAGR 3-Years
177%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
29%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Operating Income
-kr62.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-15%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Operating Income
kr251k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Operating Income
€67.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
S2Medical AB (publ)
Glance View
S2Medical AB engages in research and development in biotechnology. The company is headquartered in Linkoping, Ostergotland. The company went IPO on 2018-11-28. The firm focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The firm's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The firm is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.
See Also
What is S2Medical AB (publ)'s Operating Income?
Operating Income
-2.7m
SEK
Based on the financial report for Dec 31, 2025, S2Medical AB (publ)'s Operating Income amounts to -2.7m SEK.
What is S2Medical AB (publ)'s Operating Income growth rate?
Operating Income CAGR 5Y
29%
The average annual Operating Income growth rates for S2Medical AB (publ) have been 54% over the past three years , 29% over the past five years .
